1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Hereditary Angioedema Market
2.2. Global Hereditary Angioedema Market, By Drug Class, 2023 (US$ Million)
2.3. Global Hereditary Angioedema Market, By Product Drugs, 2023 (US$ Million)
2.4. Global Hereditary Angioedema Market, By Geography, 2023 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2023

3. Hereditary Angioedema Market: Competitive Analysis
3.1. Market Positioning of Key Hereditary Angioedema Market Vendors
3.2. Strategies Adopted by Hereditary Angioedema Market Vendors
3.3. Key Industry Strategies
4. Hereditary Angioedema Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Hereditary Angioedema Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Hereditary Angioedema Market: By Drug Class, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. C1 Esterase Inhibitors
5.3.1.1. Berinert
5.3.1.2. Haegarda
5.3.1.3. Cinryze
5.3.1.4. Ruconest
5.3.2. Kallikrien Inhibitor
5.3.2.1. Kalbitor
5.3.3. Selective Bradykinin B2 Receptor Antagonist
5.3.3.1. Firazyr
5.3.4. Others

6. Hereditary Angioedema Market: By Product Drugs, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2023 Versus 2032
6.3. Market Segmentation
6.3.1. Phase III Drug
6.3.1.1. DX-2930
6.3.2. Phase II Drug (Qualitative Information)
6.3.2.1. BCX-7353


7. North America Hereditary Angioedema Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Hereditary Angioedema Market: By Drug Class, 2022-2032, USD (Million)
7.3. Hereditary Angioedema Market: By Product Drugs, 2022-2032, USD (Million)
7.4.Hereditary Angioedema Market: By Region, 2022-2032, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. Hereditary Angioedema Market: By Drug Class, 2022-2032, USD (Million)
7.4.1.1.2. Hereditary Angioedema Market: By Product Drugs, 2022-2032, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. Hereditary Angioedema Market: By Drug Class, 2022-2032, USD (Million)
7.4.1.2.2. Hereditary Angioedema Market: By Product Drugs, 2022-2032, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. Hereditary Angioedema Market: By Drug Class, 2022-2032, USD (Million)
7.4.1.3.2. Hereditary Angioedema Market: By Product Drugs, 2022-2032, USD (Million)

8. UK and European Union Hereditary Angioedema Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Hereditary Angioedema Market: By Drug Class, 2022-2032, USD (Million)
8.3. Hereditary Angioedema Market: By Product Drugs, 2022-2032, USD (Million)
8.4.Hereditary Angioedema Market: By Region, 2022-2032, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. Hereditary Angioedema Market: By Drug Class, 2022-2032, USD (Million)
8.4.1.1.2. Hereditary Angioedema Market: By Product Drugs, 2022-2032, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. Hereditary Angioedema Market: By Drug Class, 2022-2032, USD (Million)
8.4.1.2.2. Hereditary Angioedema Market: By Product Drugs, 2022-2032, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. Hereditary Angioedema Market: By Drug Class, 2022-2032, USD (Million)
8.4.1.3.2. Hereditary Angioedema Market: By Product Drugs, 2022-2032, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. Hereditary Angioedema Market: By Drug Class, 2022-2032, USD (Million)
8.4.1.4.2. Hereditary Angioedema Market: By Product Drugs, 2022-2032, USD (Million)
8.4.1.5. France
8.4.1.5.1. Hereditary Angioedema Market: By Drug Class, 2022-2032, USD (Million)
8.4.1.5.2. Hereditary Angioedema Market: By Product Drugs, 2022-2032, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. Hereditary Angioedema Market: By Drug Class, 2022-2032, USD (Million)
8.4.1.6.2. Hereditary Angioedema Market: By Product Drugs, 2022-2032, USD (Million)

9. Asia Pacific Hereditary Angioedema Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Hereditary Angioedema Market: By Drug Class, 2022-2032, USD (Million)
9.3. Hereditary Angioedema Market: By Product Drugs, 2022-2032, USD (Million)
9.4.Hereditary Angioedema Market: By Region, 2022-2032, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. Hereditary Angioedema Market: By Drug Class, 2022-2032, USD (Million)
9.4.1.1.2. Hereditary Angioedema Market: By Product Drugs, 2022-2032, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. Hereditary Angioedema Market: By Drug Class, 2022-2032, USD (Million)
9.4.1.2.2. Hereditary Angioedema Market: By Product Drugs, 2022-2032, USD (Million)
9.4.1.3. India
9.4.1.3.1. Hereditary Angioedema Market: By Drug Class, 2022-2032, USD (Million)
9.4.1.3.2. Hereditary Angioedema Market: By Product Drugs, 2022-2032, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. Hereditary Angioedema Market: By Drug Class, 2022-2032, USD (Million)
9.4.1.4.2. Hereditary Angioedema Market: By Product Drugs, 2022-2032, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. Hereditary Angioedema Market: By Drug Class, 2022-2032, USD (Million)
9.4.1.5.2. Hereditary Angioedema Market: By Product Drugs, 2022-2032, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. Hereditary Angioedema Market: By Drug Class, 2022-2032, USD (Million)
9.4.1.6.2. Hereditary Angioedema Market: By Product Drugs, 2022-2032, USD (Million)

10. Latin America Hereditary Angioedema Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Hereditary Angioedema Market: By Drug Class, 2022-2032, USD (Million)
10.3. Hereditary Angioedema Market: By Product Drugs, 2022-2032, USD (Million)
10.4.Hereditary Angioedema Market: By Region, 2022-2032, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. Hereditary Angioedema Market: By Drug Class, 2022-2032, USD (Million)
10.4.1.1.2. Hereditary Angioedema Market: By Product Drugs, 2022-2032, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. Hereditary Angioedema Market: By Drug Class, 2022-2032, USD (Million)
10.4.1.2.2. Hereditary Angioedema Market: By Product Drugs, 2022-2032, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. Hereditary Angioedema Market: By Drug Class, 2022-2032, USD (Million)
10.4.1.3.2. Hereditary Angioedema Market: By Product Drugs, 2022-2032, USD (Million)

11. Middle East and Africa Hereditary Angioedema Market, 2022-2032, USD (Million)
11.1. Market Overview
11.2. Hereditary Angioedema Market: By Drug Class, 2022-2032, USD (Million)
11.3. Hereditary Angioedema Market: By Product Drugs, 2022-2032, USD (Million)
11.4.Hereditary Angioedema Market: By Region, 2022-2032, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. Hereditary Angioedema Market: By Drug Class, 2022-2032, USD (Million)
11.4.1.1.2. Hereditary Angioedema Market: By Product Drugs, 2022-2032, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. Hereditary Angioedema Market: By Drug Class, 2022-2032, USD (Million)
11.4.1.2.2. Hereditary Angioedema Market: By Product Drugs, 2022-2032, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. Hereditary Angioedema Market: By Drug Class, 2022-2032, USD (Million)
11.4.1.3.2. Hereditary Angioedema Market: By Product Drugs, 2022-2032, USD (Million)

12. Company Profile
12.1. BioCryst Pharmaceuticals, Inc.
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Portfolio
12.1.4. Strategic Initiatives
12.2. Cipla, Inc.
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Product Portfolio
12.2.4. Strategic Initiatives
12.3. CSL Behring Ltd.
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Product Portfolio
12.3.4. Strategic Initiatives
12.4. Ionis Pharmaceuticals, Inc.
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Product Portfolio
12.4.4. Strategic Initiatives
12.5. iBio, Inc.
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Product Portfolio
12.5.4. Strategic Initiatives
12.6. Merck & Co., Inc.
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Product Portfolio
12.6.4. Strategic Initiatives
12.7. Pharming Group NV
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Product Portfolio
12.7.4. Strategic Initiatives
12.8. Sanofi N.V.
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Product Portfolio
12.8.4. Strategic Initiatives
12.9. Shire plc.
12.9.1. Company Overview
12.9.2. Financial Performance
12.9.3. Product Portfolio
12.9.4. Strategic Initiatives
12.10. Teva Pharmaceutical Industries, Ltd.
12.10.1. Company Overview
12.10.2. Financial Performance
12.10.3. Product Portfolio
12.10.4. Strategic Initiatives
12.11. Other Notable Players
12.11.1. Company Overview
12.11.2. Financial Performance
12.11.3. Product Portfolio
12.11.4. Strategic Initiatives